Prague Med. Rep. 2021, 122, 140-180
https://doi.org/10.14712/23362936.2021.14
Valproate-associated Movement Disorder: A Literature Review
References
1. 2009) Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient. Aust. N. Z. J. Psychiatry 43(5), 484–485.
, L. N., Issler, C., Lafer, B. (
2. 1995) Negative myoclonus during valproate-related stupor. Neurophysiological evidence of a cortical non-epileptic origin. Electroencephalogr. Clin. Neurophysiol. 94(2), 103–108.
< , U., Gambardella, A., Zappia, M., Valentino, P., Quattrone, A. (https://doi.org/10.1016/0013-4694(94)00268-P>
3. Aguilar, L. G., Ondo, W. G. (2008) Exploring the relationship between drug-induced parkinsonism and tardive dyskinesias. Mov. Disord. 23.
4. 2007) Tic disorders associated to epilepsy: 2 cases. Mov. Disord. 22, 283.
, H., Adeva-Bartolomé, T., Jiménez-Jiménez, F. (
5. 1993) Parkinsonian syndrome in childhood after sodium valproate administration. Clin. Neuropharmacol. 16(5), 451–455.
< , M. J., Vaamonde, J., Narbona, J., Barao, M., Barona, P., Brannan, T., Gudin, M., Ibañez, R. (https://doi.org/10.1097/00002826-199310000-00009>
6. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Association Publishing, Washington D.C.
7. 2010) Síntomas neuropsiquiátricos causados por ácido valproico. Rev. Neurol. 50(1), 62–63.
, R., García-Espinosa, A., Pérez-Montoto, A., Toledo-Sotomayor, G., Remón-González, Y., Frades-García, V. (
8. 1996) Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 47(3), 626–635.
< , C., Shin, C., Miller, P., Carwile, S., Brown, E., Edinger, J. D., Paul, R. G. (https://doi.org/10.1212/WNL.47.3.626>
9. 2015) Clinically silent idiopathic Parkinson’s disease unmasked by valproate use: a brief report. Aging Clin. Exp. Res. 27(3), 387–390.
< , D., Batley, R., Ellis, C. (https://doi.org/10.1007/s40520-014-0278-z>
10. 2008) Stuttering as a side-effect of divalproex sodium. Psychiatry Clin. Neurosci. 62(6), 748–748.
, B., Margetić, B. (
11. 2018) Parkinsonism due to the use of long-term high-dose valproic acid in an elderly patient with mania syndrome: a case report and literature review. Psychiatry and Behavioral Sciences 8(4), 199–203.
, D. S., Aral, G., Tiryaki, A. (
12. 1994) Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem. Int. 24(1), 67–72.
, M. M., Subhash, M., Lakshmana, K. M., Rao, B. S. R. (
13. 2021) Valproate-induced rest tremor and parkinsonism. Acta Neurol. Belg. 121, 515–519.
< , J. F., Alonso-Juarez, M. (https://doi.org/10.1007/s13760-019-01239-8>
14. 2002) Reversible parkinsonism induced by prolonged treatment with valproate. Therapie 57(4), 410–411. (in French)
, B. (
15. 2013) Acute cervical dystonia after the first dose of butamirate citrate. Pediatr. Emerg. Care 29(1), 80–81.
< , E., Karakaya, P., Topcu, Y., Yis, U., Hiz, S. (https://doi.org/10.1097/PEC.0b013e31827b5635>
16. Bennett, A., Rosen, J. (2019) Valproate-induced parkinsonism: A literature review and case series. American Psychiatric Association Annual Meeting.
17. 2017) Trismus secondary to valproate treatment in a woman with bipolar disorder: a case report. Archives of Clinical Psychiatry (Sao Paulo) 44(5), 137–137.
< , M., Gracia, D., Garcia, D., Cunha, E., Campos, F., Santistevan, T., Motta, G. (https://doi.org/10.1590/0101-60830000000138>
18. 2016) Dopamine transporter single-photon emission computed tomography brain scan: A reliable way to distinguish between degenerative and drug-induced parkinsonism. Indian J. Nucl. Med. 31(3), 249–250.
< , S., Shankar, P. V., Elkider, M. (https://doi.org/10.4103/0972-3919.183620>
19. 2017) Referral practice, reporting standards, and the impact of dopamine transporter scans done in a tertiary hospital. Neurol. India 65(6), 1264–1270.
< , S., Chalissery, A. J., Barry, T., O’Sullivan, D., O’Connell, M., Lynch, T. (https://doi.org/10.4103/0028-3886.217946>
20. 1981) Asterixis associated with sodium valproate. Neurology 31(2), 194–195.
< , J., Morris, H., Golden, G. (https://doi.org/10.1212/WNL.31.2.194>
21. 2011) Drug-induced parkinsonism: A review of 17 years’ experience in a regional pharmacovigilance center in France. Mov. Disord. 26(12), 2226–2231.
< , E., Perez-Lloret, S., Bagheri, H., Brefel, C., Rascol, O., Montastruc, J.-L. (https://doi.org/10.1002/mds.23828>
22. 2007) Multiple system atrophy due to prolonged valproic acid treatment. Int. Psychogeriatr. 19(4), 780–782.
< , B., Rosati, A., Costanzi, C., Zulli, R., Mardighian, D., Gasparotti, R., Padovani, A. (https://doi.org/10.1017/S1041610207005388>
23. 2016) Reversible valproate induced Pisa syndrome and parkinsonism in a neuro-oncology patient with depression and epilepsy. Case Rep. Neurol. 8(2), 115–119.
< , A., Silvani, A., Pravettoni, G., Paoli, R. A., Lucchiari, C. (https://doi.org/10.1159/000446643>
24. 2003) Valproate. Bipolar Disord. 5(3), 189–202.
< , C. L. (https://doi.org/10.1034/j.1399-5618.2003.00031.x>
25. 1979) Hepatic failure from valproic acid. N. Engl. J. Med. 301(8), 435–436.
, T., Patel, I., Wilensky, A., Comfort, C. (
26. 2006) Drug-induced myoclonus: A French pharmacovigilance database study. Neurophysiol. Clin. 36(5–6), 333–336.
< , C., Gardette, V., Ory, F., Montastruc, J. L. (https://doi.org/10.1016/j.neucli.2006.12.003>
27. 2016) Valproate-associated parkinsonism: A critical review of the literature. CNS Drugs 30(6), 527–540.
< , F., Bhatia, K. P., Besag, F. M. C. (https://doi.org/10.1007/s40263-016-0341-8>
28. 2016) A complex hyperkinesia induced by valproate. Mov. Disord. Clin. Pract. 3(5), 513–514.
< , E., Holmes, P., Koutroumanidis, M. (https://doi.org/10.1002/mdc3.12324>
29. 1983) Alterations of the state of consciousness induced by valproic acid: 6 case reports. Riv. Patol. Nerv. Ment. 104(1), 23–34. (in Italian)
, R., Paganini, M., Boncinelli, L., Zaccara, G., Arnetoli, G., Zappoli, R. (
30. 2017) Non-hyperammonaemic valproate encephalopathy after 20 years of treatment. Epilepsy Behav. Case Rep. 8, 9–11.
< , E., Isaacs, J. D., Cock, H. R. (https://doi.org/10.1016/j.ebcr.2017.04.002>
31. ClinCalc (2020) The Top 300 of 2020. Available at: https://clincalc.com/DrugStats/Top300Drugs.aspx
32. 2001) Acute akathisia and sodium valproate. Int. J. Psychiatry Clin. Pract. 5(3), 219–222.
< , F. H. (https://doi.org/10.1080/136515001317021716>
33. 1992) Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J. Pediatr. 120(4 Pt 1), 634–638.
< , J. C., Kriel, R. L., Jones-Saete, C. M., Ong, B. Y., Jancik, J. T., Remmel, R. P. (https://doi.org/10.1016/S0022-3476(05)82496-5>
34. 1999) Extrapyramidal symptoms associated with the adjunct of nortriptyline to a venlafaxine-valproic acid combination. Int. Clin. Psychopharmacol. 14(3), 197–198.
< , D., Borgherini, G., Fiorellini Bernardis, L. A., Magni, G. (https://doi.org/10.1097/00004850-199905030-00010>
35. 2008) Parkinsonism and tardive antecollis in frontotemporal dementia – Increased sensitivity to newer antipsychotics? Eur. J. Neurol. 15(2), 199–201.
< , K., Kumar, N., Josephs, K. A. (https://doi.org/10.1111/j.1468-1331.2007.02032.x>
36. 2019) 035 Valproate-induced parkinsonism “an early warning”: case reports and review of literature. J. Neurol. Neurosurg. Psychiatry 90(e7), A12–A12.
, S., Whyte, S. (
37. 2019) A case series of severe hyperammonemia encephalopathy related to valproate: Can antipsychotics increase the risk? Iran. J. Psychiatry 14(3), 248–252.
, E., Radmehr, M., Ghaeli, P., Mousavi, M. (
38. 2011) Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine. J. Clin. Pharm. Ther. 36(3), 430–432.
< , C., Fudio, S., Lorenzo, A. (https://doi.org/10.1111/j.1365-2710.2010.01197.x>
39. 2018) No longer lost in translation: Evidence that Google Translate works for comparative bag-of-words text applications. Polit. Anal. 26(4), 417–430.
< , E., Schoonvelde, M., Schumacher, G. (https://doi.org/10.1017/pan.2018.26>
40. 2008) Valproate-induced hyperammonemic encephalopathy without cognitive sequelae: A case report in the psychiatric setting. J. Neuropsychiatry Clin. Neurosci. 20(3), 369–371.
< , M.-J. C. C., Sarazin, F. F. A. (https://doi.org/10.1176/jnp.2008.20.3.369>
41. 1995) Parkinsonism induced by sodium valproate. Neurologia 10(9), 381–383. (in Spanish)
, M. A., Sanz Martínez, J., Vaamonde Gamo, J., Gudín Rodríguez-Magariños, M., Ibáñez Alonso, R., Riñón, V. (
42. 2005) Drug-induced movement disorders caused by medications other than dopamine receptor blockers in the Veteran population. Mov. Disord. 20, 17–18.
, S., Ferrer, M., Cheng, E., Sayers, J. (
43. Desai, D., Desai, S. (2015) Spectrum of disorders presenting as secondary Parkinsonism in a rural based medical teaching college in Western India. Mov. Disord. 30.
44. 1980) Extrapyramidal syndrome with sodium valproate. Br. Med. J. 280(6208), 189.
< , D., Saunders, M. (https://doi.org/10.1136/bmj.280.6208.189-a>
45. 2008) Acute Pisa syndrome and pharnygolaryngeal dystonia due to ziprasidone. J. Neuropsychiatry Clin. Neurosci. 20(1), 108–109.
< , H. S. (https://doi.org/10.1176/jnp.2008.20.1.108>
46. 1999) Olanzapine-induced tardive dystonia. Am. J. Psychiatry 156(10), 1662.
< , E., Strakowski, S. M. (https://doi.org/10.1176/ajp.156.10.1662>
47. 2004) Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 62(8), 1435–1437.
< , K., Clough, P., Kellett, M., Fallon, K., Duncan, S. (https://doi.org/10.1212/01.WNL.0000121228.32913.00>
48. 2011) Reversible dementia and gait disturbance after prolonged use of valproic acid. Seizure 20(6), 509–511.
< , M. D., Shinar, R., Yaari, R. (https://doi.org/10.1016/j.seizure.2011.02.009>
49. 2008) Lamotrigine might potentiate valproic acid-induced hyperammonemic encephalopathy. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(7), 1747–1748.
< , C. C., Huang, M. C., Liu, H. C. (https://doi.org/10.1016/j.pnpbp.2008.06.006>
50. 2015) Pisa syndrome associated with clozapine: A rare case report and literature review. Spine Deform. 3(4), 386–389.
< , F., Omidi-Kashani, F., Baradaran, A. (https://doi.org/10.1016/j.jspd.2015.02.003>
51. 2004) Sodium valproate induced parkinsonism. Epilepsia 45, 132.
, A., De Merra, F., Filosto, M., Leonardi, A. (
52. 2002) Divalproex-induced parkinsonism: A retrospective review of cases. Mov. Disord. 17, 250–251.
, C., Slevin, J., Kasarskis, E. (
53. 1983) Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatr. Scand. 67(3), 178–187.
< , T., Christensen, T. R., Gerlach, J. (https://doi.org/10.1111/j.1600-0447.1983.tb00339.x>
54. 1994) A reversible parkinsonian syndrome and hepatotoxicity following addition of carbamazepine to sodium valproate. Aust. N. Z. J. Med. 24(4), 413–414.
< , P. R., Stewart, M. R. (https://doi.org/10.1111/j.1445-5994.1994.tb01479.x>
55. 2000) Adverse response to methylphenidate in combination with valproic acid. J. Child Adolesc. Psychopharmacol. 10(1), 39–43.
< , L., Roberts, W. (https://doi.org/10.1089/cap.2000.10.39>
56. 2009) Valproic acid-induced myoclonus in a demented patient: a case report. Case Rep. Med. 2009, 392091.
< , T. M., Aziz, R., Muralee, S., Tampi, R. R. (https://doi.org/10.1155/2009/392091>
57. 1985) Encephalopathy with asterixis induced by sodium valproate. Role of hyperammonemia without hepatic insufficiency. Presse Med. 14(7), 431. (in French)
, J. L., Mege, J. L. (
58. 2006) Loss of autonomy related to valproic acid intake. J. Am. Geriatr. Soc. 54(12), 1971–1971.
< , M. L., Cougnaud, A., Ghali, A., Bruhat, C., Diquet, B., Berrut, G. (https://doi.org/10.1111/j.1532-5415.2006.00991.x>
59. 2014) Valproate-induced generalized choreoathetosis. Mov. Disord. Clin. Pract. 1(3), 271–272.
< , A., Amboni, M., Tessitore, A. (https://doi.org/10.1002/mdc3.12069>
60. 2013) Reversible vertical gaze palsy in sodium valproate toxicity. J. Neuroophthalmol. 33(2), 202–203.
< , S., Srinivas, M., Raghunandan, N., Thomas, M., Prabhu, A., Laly, M. (https://doi.org/10.1097/WNO.0b013e318283bcc0>
61. 2002) Reversible valproate-induced choreiform movements. Seizure 11(3), 205–206.
< , D. I., Guleryuz, M., Bingol, C. A. (https://doi.org/10.1053/seiz.2001.0576>
62. 1997) Risperidone‐induced tardive dyskinesia and parkinsonism. Mov. Disord. 12(1), 119–121.
< , K. A., Caviness, J. N. (https://doi.org/10.1002/mds.870120123>
63. 2007) Cervical dystonia due to interaction of valproic acid and quetiapine. J. Clin. Psychopharmacol. 27(4), 396–397.
< , B., Rabovsky, K., Jentzsch, C., Pinhard, K., Müller-Spahn, F. (https://doi.org/10.1097/01.jcp.0000264989.63227.82>
64. 2004) Adult nonketotic hyperglycinemia (NKH) crisis presenting as severe chorea and encephalopathy. Mov. Disord. 19(4), 485–486.
< , D. A., Ringel, S. P. (https://doi.org/10.1002/mds.10681>
65. 2016) Reversible valproic acid-induced parkinsonism and cognitive impairment in an elderly patient with bipolar disorder I. Turk Psikiyatri Derg. 27(3), 213–217. (in Turkish, English)
, S., Waller, S., Reese, K., Testa, C. (
66. 2017) Disabling tremor induced by long-term use of sodium valproate and lamotrigine: case report. Medicine 96(47), e8711.
< , Z. F., Chen, J., Zhou, C. N., Rao, Z., Wang, X. H. (https://doi.org/10.1097/MD.0000000000008711>
67. 2003) The history of valproate in clinical neuroscience. Psychopharmacol. Bull. 37, 5–16 (Suppl. 2).
, T. R. (
68. 2007) Reversible cognitive and neurological symptoms during valproic acid therapy. J. Am. Geriatr. Soc. 55(4), 628–628.
< , C., Mondon, K., de Toffol, B., Constans, T. (https://doi.org/10.1111/j.1532-5415.2007.01117.x>
69. 2002) Valproate-induced parkinsonism in a demented elderly patient. J. Clin. Psychiatry 63(1), 75.
< , M. (https://doi.org/10.4088/JCP.v63n0114a>
70. Irons, R., Joanna, B., Apurba, C. (2015) The role of DaT scan in drug induced Parkinsonism. Mov. Disord. 30.
71. 2013) Risperidone-induced Pisa syndrome in MS: Resolution with lurasidone and recurrence with chlorpromazine. Ann. Pharmacother. 47(9), 1223–1228.
< , C. A., Diefenderfer, L. A. (https://doi.org/10.1177/1060028013503132>
72. 2007) Valproate-induced Parkinsonism in epilepsy patients. Mov. Disord. 22(1), 130–133.
< , D., Lim, S.-H., Pan, A., Tan, L., Tan, E.-K. (https://doi.org/10.1002/mds.21188>
73. Jankovic, J., Tolosa, E. (2007) Parkinson’s Disease and Movement Disorders. Lippincott Williams and Wilkins, Baltimore.
74. 2014) Parkinsonian syndrome, a sporadic side effect of valproic acid. Pharmacother. Psychiatr. Neurol. 23(3–4), 199–205.
, A., Kurkowska-Jastrzebska, I. (
75. 2001) Valproate asterixis: a case report. Acta Neurol. Taiwan. 10(2), 123–126.
, C.-D., Chen, W.-T., Chen, J., Yen, D.-J., Yiu, C.-H., Liao, K.-K. (
76. 2010) Valproate-induced reversible “Parkinsonism Plus” syndrome. J. Indian Acad. Clin. Med. 11, 235–238.
, G. A., Ranjan, R., Gupta, M., Chowdhry, D., Hirve, M. (
77. Kim, H., Park, H., Sung, Y., Lee, H., Kim, D., Choi, S. (2018) Valproic acid related reversible parkinsonism. Asian Oceanian Congress of Neurology.
78. 2000) A case of valproate-induced reversible parkinsonism. J. Korean Neurol. Assoc. 18(5), 654.
, S. K., Oh, S. H., Kim, W. J. (
79. 1987) Camptocormia, a new side effect of sodium valproate. Epilepsy Res. 1(4), 254–257.
< , S., Iivanainen, M. (https://doi.org/10.1016/0920-1211(87)90033-7>
80. 2019) Akinetisch-rigide Bewegungsstörungen unter Antikonvulsiva. DGNeurologie 2(4), 287–291.
< , K., Knake, S., Timmermann, L., Rosenow, F., Strzelczyk, A. (https://doi.org/10.1007/s42451-019-0083-1>
81. 1977) Sodium valproate and clonazepam in the treatment of intractable epilepsy. Arch. Neurol. 34(1), 14–17.
< , J., Anthony, M. (https://doi.org/10.1001/archneur.1977.00500130034007>
82. 1994) Choreiform movements associated with the use of valproate. Arch. Neurol. 51(7), 702–704.
< , M. E., Asconapé, J. J., Penry, J. K. (https://doi.org/10.1001/archneur.1994.00540190086020>
83. 1999) Valproic acid intoxication in a patient with bipolar disorder and chronic uremia. Can. J. Psychiatry 44(2), 188.
, O., Dubreucq, J. L., Beauchemin, M. A., Vinet, B. (
84. 1979) Extrapyramidal syndrome with sodium valproate. Br. Med. J. 2(6197), 1035–1036.
< , A., Stanley, M., Angrist, B., Gershon, S. (https://doi.org/10.1136/bmj.2.6197.1035-a>
85. 2016) Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin. Neurol. Neurosurg. 146, 35–39.
< , L., Rouaud, T., Debilly, B., Durif, F., Houeto, J.-L., Kreisler, A., Defebvre, L., Lamy, E., Volteau, C., Nguyen, J. M., Dily, S. L., Damier, P., Boutoleau-Bretonnière, C., Lejeune, P., Derkinderen, P. (https://doi.org/10.1016/j.clineuro.2016.04.021>
86. 2004) A case of reversible parkinsonism induced by valproate in a patient with bipolar disorder. Korean J. Psychopharmacol. 15(1), 107.
, K. U. (
87. 2007) Early dystonia in probable Creutzfeldt-Jakob disease with diffusion weighted MR images. Mov. Disord. 22, 117–118.
, S., Koh, S., Park, K., Lee, D. (
88. 2001) Brief history of the development of valproate in bipolar disorders. Encephale 27(4), 365–372. (in French)
, T. (
89. 2011) Antipsychotic medication and oxidative cell stress: a systematic review. J. Clin. Psychiatry 72(3), 273–285.
< , P., Delieu, J., Mellor, R., Williams, J. H. H., Hudson, P. R., Hunter-Lavin, C. (https://doi.org/10.4088/JCP.09r05268yel>
90. 2009) Reversible dementia-like condition and parkinsonism in an elderly woman. Idiosyncratic adverse effects connected to 11 years of antiepileptic medication. Lakartidningen 106(12), 863–865. (in Swedish)
, U., Taubert, B., Fahlqvist, M. S., Bergens, A., Kimland, E., Jonsson, E. W., Bergman, U. (
91. 2002) Basic pharmacology of valproate. CNS Drugs 16(10), 669–694.
< , W. (https://doi.org/10.2165/00023210-200216100-00003>
92. 2009) Parkinsonism due to the medication. Ned. Tijdschr. Geneeskd. 153, A336–A336. (in Dutch)
, M., Tromp, S. C. (
93. 2010) Multi-centre survey of new patients referred from primary care with parkinsonism what proportion are on medications which can cause drug induced parkinsonism? Mov. Disord. 25(7), 224.
, V., Henderson, E., Ahearn, D., MacMahon, D. (
94. 2005) Valproate induced parkinsonism. J. R. Coll. Physicians Edinb. 35(3), 214.
, G. (
95. 2007) Diagnosis of Parkinsonism in older patients receiving sodium valproate. Mov. Disord. 22(8), 1211–1211.
< , G. J. A., Stewart, D. A. (https://doi.org/10.1002/mds.21514>
96. 2011) Valproic acid-induced parkinsonism in the elderly: A comprehensive review of the literature. Am. J. Geriatr. Pharmacother. 9(6), 405–412.
< , F., Tampi, R. R. (https://doi.org/10.1016/j.amjopharm.2011.09.002>
97. 2018) Side effects of sodium valproate in a Tunisian population. Res. J. Nerv. Syst. 1(1), 8.
, S., Mansour, M., Msselmeni, M., Bedoui, I., Zaouali, J. (
98. 2013) Valproate-induced hyperammonemic encephalopathy: a case report. Innov. Clin. Neurosci. 10(5–6), 12–13.
, V., Sarwar, S., Rosenberger, R., Rais, T., Knox, M. (
99. 2000) Dementia and extrapyramidal problems caused by long-term valproic acid. Therapie 55(5), 629–634.
, K., Gras-Champel, V., Bonnet, I., Pannier, M., Masson, H., Rosa, A., Andrejak, M. (
100. 2006) Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 39(1), 9–12.
< , K., Gras-Champel, V., Masson, H., Andréjak, M. (https://doi.org/10.1055/s-2006-931471>
101. 2008) Valproate-induced parkinsonism in epilepsy patient – A case report. Acta Medica Bulgarica XXXV(1/2008), 38–42.
, K., Maximov, G. (
102. 2006) Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. Pediatr. Neurol. 35(5), 356–358.
< , P. F., Sankar, R., Shields, W. D. (https://doi.org/10.1016/j.pediatrneurol.2006.06.009>
103. 2015) Divalproex-induced stuttering: A rare case report. Eur. J. Psychol. Educ. Studies 2(1), 25.
, S., Sen, S., Chatterjee, S. S., Biswas, A., Tripathi, S. K. (
104. 2010) The differential diagnoses of parkinsonism: Findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. Clin. Neurol. Neurosurg. 112(5), 431–435.
< , R. P., Werneck, L. C., Teive, H. A. G. (https://doi.org/10.1016/j.clineuro.2010.03.003>
105. 1981) A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30(2), 239–245.
< , C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., Greenblatt, D. J. (https://doi.org/10.1038/clpt.1981.154>
106. 2012) Asterixis (flapping tremors) as an outcome of complex psychotropic drug interaction. J. Neuropsychiatry Clin. Neurosci. 24(1), E26–E27.
< , R., Pandurangi, A., Bhogale, G., Patil, N., Chate, S. (https://doi.org/10.1176/appi.neuropsych.10110266>
107. 1999) Prospective evaluation of parkinsonism and tremor in patients treated with valproate. Parkinsonism Relat. Disord. 5(1–2), 67–68.
< , M., García, M., Rabinowicz, A., Merello, M. (https://doi.org/10.1016/S1353-8020(99)00013-9>
108. 1979) Treatment of Parkinson’s disease with sodium valproate: Clinical, pharmacological, and biochemical observations. Can. J. Neurol. Sci. 6(3), 337–343.
< , J., Williams, A., Plotkin, C., Eng, N., Ziegler, M., Calne, D. (https://doi.org/10.1017/S0317167100023970>
109. 2004) Spasmodic dysphonia induced by valproic acid. Epilepsia 45(7), 880–881.
< , J., Park, K. D., Cho, H. J., Choi, K. G., Jung, S. M. (https://doi.org/10.1111/j.0013-9580.2004.69603.x>
110. 1998) Reversible parkinsonism induced by prolonged treatment with valproate. J. Neurol. 245(12), 794–796.
< , M., Thomas, A., Paci, C. (https://doi.org/10.1007/s004150050288>
111. 2014) Asterixis: A study of 103 patients. Metab. Brain Dis. 29(3), 813–824.
< , G., Lin, M. M., Laureno, R. (https://doi.org/10.1007/s11011-014-9514-7>
112. 1998) Valproate induced parkinsonism. No To Shinkei 50(1), 81–84.
, Y. C., Tazawa, T. (
113. 2018) Valproate induced Parkinsonism. Natl. J. Integr. Res. Med. 9(6), 72–74.
, S. R., Patel, K. P., Gupta, S. D., Malhotra, S. D., Patel, P. R. (
114. 2010) Syndrome démentiel et extrapyramidal iatrogène: Effet secondaire rare de l’association acide valproïque-aspirine. Presse Med. 39(2), 279–280.
< , J.-P., Pradeau, F. (https://doi.org/10.1016/j.lpm.2009.02.024>
115. 1990) Reversible parkinsonism associated with valproate therapy. Neurology 40, 139 (Suppl. 1).
, C., Blume, W., Young, G. (
116. 2015) Valproate can induce reversible encephalopathy. Ugeskr. Laeger 177(20), 945–946 (in Danish).
, S., Harbo, T., Christensen, J. (
117. 2002) Valproate and quetiapine overdose with benign outcome: a case report. Int. J. Psychiatry Clin. Pract. 6(3), 173–174.
< , M., Azzoni, A. (https://doi.org/10.1080/136515002760276117>
118. 2019) Drug-induced parkinsonism may persist beyond two years after discontinuation of dopamine transmission blocking agents. Mov. Disord. 34, 599.
, J., Mehanna, R. (
119. 2003) Acute akinetic crisis with marked cognitive impairment due to valproate treatment. Int. J. Geriatr. Psychiatry 18(4), 356–357.
< , A., Hamelbeck, B., Pfuhlmann, B. (https://doi.org/10.1002/gps.729>
120. 2004) Encephalopathy and myoclonus triggered by valproic acid. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(6), 1061–1063.
< , A., Leonhard, C., Mössner, R., Lesch, K.-P., Fallgatter, A. J. (https://doi.org/10.1016/j.pnpbp.2004.05.041>
121. 2005) A case of Parkinsonian syndrome, cognitive impairment and hyperammonemia induced by divalproate sodium prescribed for bipolar disorder. Encephale 31(1), 98–101. (in French)
< , C., Martin, K., Tournier, M., Bégaud, B., Verdoux, H. (https://doi.org/10.1016/S0013-7006(05)82378-4>
122. 2019) Comment: Dystonia and asterixis in acute thalamic infarct: Proposed mechanism. Ann. Mov. Disord. 2(3), 138–139.
< , J. P., Caprara, A. L. F. (https://doi.org/10.4103/AOMD.AOMD_22_19>
123. 2019) Valproic acid-associated pancytopenia: A dose-dependent adverse effect. Rom. J. Neurol. 18(3), 150–153.
< , J. P., Caprara, A. L. F., Silveira, J. O. F. (https://doi.org/10.37897/RJN.2019.3.9>
124. 2006) The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: A study of 364 patients with different types of epilepsy. Epilepsia 47(12), 2183–2185.
< , A. J., Vojvodić, N., Janković, S., Sindelić, A., Sokić, D. (https://doi.org/10.1111/j.1528-1167.2006.00711.x>
125. 2000) Valproinsäure als Phasenprophylaktikum Ein Fall von Valproat-Enzephalopathie. Nervenarzt 71(5), 401–403.
< , K. G., Weiss-Brummer, J., Wieland, U., Schmauß, M. (https://doi.org/10.1007/s001150050575>
126. 2008) Pisa syndrome and parkinsonism secondary to valproic acid in Huntington’s disease. Mov. Disord. 23(16), 2430–2431.
< , Z., Tschopp, L., Calandra, C., Micheli, F. (https://doi.org/10.1002/mds.22328>
127. Sarna, J., Pringsheim, T. (2011) Progressive supranuclear palsy-like phenotype associated with concomitant exposure to mood stabilizer and neuroleptic. Mov. Disord. 26.
128. 1994) Reversible valproate-induced extrapyramidal disorders. Epilepsia 35(2), 391–393.
< , E., Delsoldato, S., Negrotti, A., Mancia, D. (https://doi.org/10.1111/j.1528-1157.1994.tb02449.x>
129. 1990) Striatal function in normal aging: Implications for Parkinson’s disease. Ann. Neurol. 28(6), 799–804.
< , G., Colebatch, J., Shah, A., Brooks, D., Marsden, C., Frackowiak, R. (https://doi.org/10.1002/ana.410280611>
130. 2009) Cognitieve stoornissen en parkinsonisme bij gebruik van valproïnezuur. Tijdschr. Gerontol. Geriatr. 40(1), 29–33.
< , L., Middeljans-Tijssen, C. W., Hengstman, G. J. D., Olde Rikkert, M. G. M. (https://doi.org/10.1007/BF03088474>
131. 2008) Valproate-induced parkinsonism, glial cells and Alexander’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(5), 1351–1352.
< , G. P., Conti, M., Sau, G. F., Cocco, G. A. (https://doi.org/10.1016/j.pnpbp.2008.03.022>
132. 2000) Valproic acid toxicity mimicking multiple system atrophy. Neurology 55(12), 1936–1937.
< , H. A., Fife, T. D. (https://doi.org/10.1212/WNL.55.12.1936>
133. 1999) A case of epileptic negative myoclonus: Therapeutic considerations. Brain Dev. 21(3), 209–212.
< , Y., Mitsuyoshi, I. (https://doi.org/10.1016/S0387-7604(99)00005-4>
134. 2013) Valproic acid-induced parkinsonism: Levodopa responsiveness with dyskinesia. Parkinsonism Relat. Disord. 19(8), 758–760.
< , M., Factor, S. A. (https://doi.org/10.1016/j.parkreldis.2013.03.016>
135. Simões, R., Inácio, N., Silva, V., Arraiolos, A., Alegria, P., Canas, N., Vale, J. (2016) Valproate-induced reversible parkinsonism – A case series. Mov. Disord. 31.
136. 2010) Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus. J. Am. Geriatr. Soc. 58(4), 799–801.
< , M. J. M., Beutler, J. J., Hardon, W. J., Berden, J. H. M., Verhave, J. C., Conemans, J. M. H., Hollander, D. A., Dautzenberg, P. L., Hoogeveen, E. K. (https://doi.org/10.1111/j.1532-5415.2010.02795.x>
137. 2010) Valproate-induced reversible hemichorea. Mov. Disord. 25, 1511–1512.
< , S., Lok, A. W. (https://doi.org/10.1002/mds.23119>
138. 2016) Valproate-induced hyperammonemic encephalopathy in an elderly patient with bipolar disorder. J. Geriatr. Ment. Health 3(2), 172–175.
, I., Sahoo, S., Gupta, G., Chauhan, N., Grover, S. (
139. 2017) A case of severe parkinsonism in an elderly person induced by valproic acid. Psychogeriatrics 17(1), 76–77.
< , H., Ogihara, T., Nakamura, T., Sasayama, D., Sugiyama, N., Takahashi, Y., Washizuka, S., Amano, N. (https://doi.org/10.1111/psyg.12172>
140. 2004a) Status dystonicus: Report of four cases. Mov. Disord. 19, 114.
< , H. A. G., Souza, M., Antoniuk, S., Barbosa, E., Scaff, M., Werneck, L. (https://doi.org/10.1002/mds.20249>
141. 2004b) Flunarizine and cinnarizine-induced parkinsonism: A historical and clinical analysis. Parkinsonism Relat. Disord. 10(4), 243–245.
< , H. A. G., Troiano, A. R., Germiniani, F. M. B., Werneck, L. C. (https://doi.org/10.1016/j.parkreldis.2003.12.004>
142. 2012) Late adverse effects of the coadministration of valproate and lamotrigine. Pediatr. Neurol. 47(1), 47–50.
< , S., Moreira, B., Valente, K. D. (https://doi.org/10.1016/j.pediatrneurol.2012.04.026>
143. 2005) Valproate-caused encephalopathy. Ugeskr. Laeger 167(40), 3793–3794. (in Danish)
, K. S., Wolf, P. (
144. 2008) Reversible parkinsonism and cognitive impairment following treatment with valproate. Rev. Neurol. 47(7), 390–391. (in Spanish)
, M. E., Morera-Guitart, J., Palao-Duarte, S. (
145. 2011) Acute chorea caused by valproate in an elderly. Acta Neurol. Belg. 111(3), 220–221.
, K., Cras, P., Helsen, G. (
146. 1989) Transient Parkinson syndrome and tremor caused by the use of sodium valproate. Ned. Tijdschr. Geneeskd. 133(24), 1230–1232. (in Dutch)
, A. Jr. (
147. 2000) Asterixis: An adverse event also with new anti-epileptic drugs. Epilepsia 41, 226 (Suppl. 7).
, H., Mothersill, I. (
148. 2016) Valproate for schizophrenia. Cochrane Database Syst. Rev. 11(11), CD004028.
, Y., Xia, J., Helfer, B., Li, C., Leucht, S. (
149. 2006) Dropped head syndrome in long-term care patients with chronic epilepsy and mental retardation-relationship to antiepileptic treatment. Mov. Disord. 21, 373.
, I., Bruchert, S., Meyer, K., Bohhalter, S. (
150. 1997) Extrapyramidal syndrome due to valproate administration as an adjunct to lithium in an elderly manic patient. Int. J. Geriatr. Psychiatry 12(2), 272.
< , V., Golüke-Willemse, G. (https://doi.org/10.1002/(SICI)1099-1166(199702)12:2<272::AID-GPS561>3.0.CO;2-V>
151. 2013) Methylphenidate-induced acute orofacial and extremity dyskinesia. J. Child Neurol. 28(6), 781–783.
< , A. E., Donmez, A., Orun, E., Tas, T., Isik, B., Sonmez, F. M. (https://doi.org/10.1177/0883073812449905>
152. 2006) Pisa syndrome in a patient in a wheelchair taking valproic acid. Am. J. Psychiatry 163(2), 325–326.
< , M., Aulakh, J. S., Weith, J., Hawkins, J. W. (https://doi.org/10.1176/appi.ajp.163.2.325-a>
153. 2018) DAT-SPECT imaging in cases of drug-induced parkinsonism in a specialty movement disorders practice. Parkinsonism Relat. Disord. 53, 37–41.
< , J., Koloms, K., Bega, D. (https://doi.org/10.1016/j.parkreldis.2018.04.037>
154. 2008) Movement disorders at a university hospital emergency room. An analysis of clinical pattern and etiology. J. Neurol. 255(5), 745–749.
< , J. H., Lee, P. H., Yong, S. W., Park, H. Y., Lim, T. S., Choi, J. Y. (https://doi.org/10.1007/s00415-008-0789-7>
155. 1984) Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases. Eur. Neurol. 23(2), 104–112.
< , G., Paganini, M., Campostrini, R., Arnetoli, G., Zappoli, R., Moroni, F. (https://doi.org/10.1159/000115687>
156. 2007) Movement disorders in patients taking anticonvulsants. J. Neurol. Neurosurg. Psychiatry 78(2), 147–151.
< , C., Munhoz, R. P., Asante, A. N., Politzer, N., Wennberg, R., Carlen, P., Lang, A. (https://doi.org/10.1136/jnnp.2006.100222>